According to Zacks, “CareDx, Inc. is a commercial stage company. It develops, markets, and delivers a diagnostic surveillance solution for heart transplant recipients. The Company provides AlloMap, a noninvasive blood test used to aid in the identification of heart transplant recipients. It is also pursuing other areas of transplant surveillance, such as the use of cell-free DNA (cfDNA) as a biomarker for rejection. CareDx, Inc. is based in Brisbane, California. “
CDNA has been the topic of a number of other reports. Piper Jaffray Cos. reissued an overweight rating and set a $6.00 price target on shares of CareDx in a report on Wednesday, June 15th. Mizuho increased their price target on shares of CareDx from $8.00 to $12.00 and gave the stock a buy rating in a report on Tuesday, June 14th. Finally, Leerink Swann reissued a buy rating on shares of CareDx in a report on Tuesday, June 14th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus target price of $9.25.
Shares of CareDx (NASDAQ:CDNA) traded up 1.8901% on Tuesday, hitting $3.8005. 601 shares of the stock traded hands. The company’s market cap is $72.12 million. The stock has a 50 day moving average of $4.20 and a 200 day moving average of $4.58. CareDx has a one year low of $3.28 and a one year high of $6.87.
CareDx (NASDAQ:CDNA) last released its quarterly earnings data on Wednesday, August 10th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.28) by $0.01. The business earned $10.70 million during the quarter, compared to analysts’ expectations of $10.42 million. CareDx had a negative net margin of 91.21% and a negative return on equity of 59.77%. The firm’s revenue was up 50.7% on a year-over-year basis. During the same period last year, the company earned ($0.27) earnings per share. Equities analysts anticipate that CareDx will post ($1.05) earnings per share for the current year.
In related news, major shareholder Neil Gagnon acquired 178,686 shares of CareDx stock in a transaction on Thursday, September 22nd. The stock was bought at an average cost of $4.00 per share, for a total transaction of $714,744.00. Following the completion of the transaction, the insider now owns 613,473 shares of the company’s stock, valued at approximately $2,453,892. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 13.33% of the company’s stock.
A number of institutional investors have recently bought and sold shares of the company. Royce & Associates LP boosted its position in CareDx by 15.5% in the first quarter. Royce & Associates LP now owns 85,917 shares of the company’s stock worth $426,000 after buying an additional 11,503 shares in the last quarter. Vanguard Group Inc. boosted its position in CareDx by 281.2% in the second quarter. Vanguard Group Inc. now owns 306,178 shares of the company’s stock worth $1,323,000 after buying an additional 225,863 shares in the last quarter. Gagnon Advisors LLC boosted its position in CareDx by 40.7% in the second quarter. Gagnon Advisors LLC now owns 952,464 shares of the company’s stock worth $4,105,000 after buying an additional 275,496 shares in the last quarter. Finally, Gagnon Securities LLC boosted its position in CareDx by 13.5% in the second quarter. Gagnon Securities LLC now owns 1,339,005 shares of the company’s stock worth $5,771,000 after buying an additional 159,491 shares in the last quarter. Institutional investors own 30.84% of the company’s stock.
CareDx, Inc is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CareDx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.